## Pooled Saliva Specimens for SARS-CoV-2 Testing

Barat et al. Supplementary Data

## Table S1: Summary of studies evaluating saliva as a specimen for SARS-CoV-2 testing

Reference, First Author	Characteristics	Collection Method	Total Subjects	Total Positive	Sensitivity/ PPA (%) SAL/ NP	Specificity / NPA (%) SAL/NP	Testing Platform and Notes
Jamal (1)	All known positive	Saliva	91	72	72 SAL	-	Allplex™ 2019-nCoV Assay(100T) (Seegene
		NP swab			89 NP		Inc, Seoul, Korea)
							Saliva + PBS
Nagura-Ikeda (2)	15 asymptomatic,	Saliva	103	103	SAL	-	RT-qPCR LDT, cobas SARS-CoV-2 high-
	88 symptomatic	OP/NP for diagnosis			82 LDT		throughput system, RT- LAMP <sup>1</sup>
	All known positive				81 COBAS		Saliva + PBS
					71 RT-LAMP		
Wyllie (3)	In-patient	Saliva upon waking prior to	70	70	81 SAL	-	CDC Assav
, - (- )	<b>P</b>	food/water intake			71 NP		,
							Viral load higher in
	Asymptomatic health-care	NP swab	495	9	Only 9 positive samples for		saliva in patients
	workers	Self- collected NP for asymptomatic <sup>2</sup>			comparison		

Migueres (4)	17 Asymptomatic	Saliva	123	44	88 SAL	-	Panther Fusion™
					asymptomatic		module (Hologic)
	27 Symptomatic	NP swab					
					95 SAL		
	9 Hospitalized				symptomatic		
					93 NP		
Skolimowska	Symptomatic	Saliva	132	18	83 SAL	99 SAL	Roche, AusDiagnostics,
(5)	healthcare workers						ThermoFisher, Abbott
		Combined OP/NP swab					
	5 pediatric patients	comparison					cobas
	(<18 years)						
Pasomsub (6)	Symptomatic	Saliva	200	19	84 SAL	99 SAL	SARS-CoV-2 Nucleic Acid
							Diagnostic Kit (Sansure,
		NP and throat swab					Changsha, China)
							CFX96 Real-Time
							Detection System (Bio-
							Rad)
Williams (7)	Screening clinic	Saliva	522	39	85 SAL	98 SAL	Coronavirus Typing (8-
							well) assay,
		NP swab					AusDiagnostics)
							Higher viral load in NP
Zhu (8)		Saliva	944	442	86 SAL	97 SAL	
		Respiratory tract sample					
		(NP/OP swab)					

Landry (9)	Symptomatic out- patient	Saliva NP swab	124	35	86 SAL 94 NP	98 SAL	CDC Assay 1/3 saliva samples were thick
Rao (10)	Asymptomatic adult male, 8-10 day after tested positive SAL from deep in throat upon waking prior to food/water intake	Saliva NP swab	217	160	93 SAL 53 NP	-	One-step RT-PCR , Real- Q 2019 nCoV detection kit (Biosewoom, Inc, South Korea) Higher viral load in saliva
Hanson (11)	Drive-thru test center	Saliva NP swab	354	81	94 SAL	98 SAL	Hologic Aptima SARS- CoV-2 transcription mediated amplification (TMA) assay Saliva + Universal transport media
McCormick- Baw (12)	Emergency department	Saliva NP swab	156	50	96 SAL	99 SAL	Cepheid Xpert Xpress SARS27 CoV-2 PCR test
Procop (13)	Screening Center	Elicited cough and saliva NP swab	216	38	100 SAL PPA	99 SAL NPA	Aptima™ SARS-CoV-2 transcription mediated amplification assay (Panther™ System, Hologic)

Azzi (14)	Confirmed COVID-	Saliva (drooling technique)	25	25	100 SAL	-	Abi Prism 7000
	19 patients with	Or Endotracheal tube					sequence detection
	severe or very						system (Applied
	severe disease	NP swab					Biosystems)
							QIAmp Viral RNA mini
							kit (Qiagen)
							Luna Universal qPCR
							Master Mix (New
							England BioLab)
Iwasaki (15)	Symptomatic	Saliva	76	9	97 Overall	-	
					percent		One-Step Real-Time
		NP swab			agreement		RIPCR Master Mixes
							and tepOnePlus Real
							Time PCR System
							(Inermo Fisher
Lhuamina	22 hospitalized	Coline	1 4 7	22	97 Overall		Scientific)
Uwamino (16)	32 nospitalized	Sdiiva	147	52	87 Overall	-	LightCycler96 (Roche,
(10)	patients	ND cwah					Basel, Switzenand)
	11E symptomatic	INP SWab			(SAL & NP)		2010 Novel Corepositive
	staff				96 ovorall		2019 Novel Colonavirus
	Stati				concordance		Kvoto Japan)
					within first 10		Kyoto, Japanj
					davs		
Byrne (17)	Emergency	Saliva	110	14	86 541	_	OIAmn Viral RNA Mini
Dyrne (17)	Department	Suiva	110	14	00 5/12		Kit (OIAGEN)
	Department	Nasal and throat swab					Genesig Real-time
	In-patient						Coronavirus COVID-19
	symptomatic						PCR
	, p						Similar viral load

<sup>1</sup>RT-LAMP : Reverse transcription-loop-mediated isothermal amplification

<sup>2</sup>All NP/OP healthcare collected except when noted

	ED	Drive- Through	Total
Number of Participants	69	380	449
Gender, Male N (%)	23 (33%)	159 (42%)	182 (41%)
Age, Range (median)	21-88 (46)	21-75 (42)	21-88 (42)

## **Table S2: Study Participant Characteristics**

Figure S1.



N2 Ct Values for Sample Pairs

**Figure S1. N2 Cycle threshold (Ct) values for paired NP/MT and SAL samples (29 pairs).** Pairs are connected by a line. The N2 Ct was set to 40 for samples in which N2 was not detected, indicating a negative result for SARS-CoV-2 RNA. Horizontal dashed line is at Ct=40, the assay cut off. P-value <0.05 calculated by Wilcoxon matched- pair signed rank test.





**Figure S2. Comparison of Cycle Threshold (Ct) values for N1 for NP versus SAL specimens (29 pairs).** Analysis demonstrates moderately good correlation between NP Ct values and Ct values for matched SAL samples. R and p values determined by Pearson correlation and graphically represented by linear regression. Dotted line indicates the limit of detection. P-value <0.001.

Figure S3 (A-B)





**Figure S3 (A-B). Concordance between SARS-CoV-2 detection in 29 samples of each type using CDC N1 primer and probe sets.** R and p values determined by Pearson correlation and graphically represented by linear regression. Dotted line indicates the limit of detection. P-value <0.001

Figure S4 (A-C)







**Figure S4 (A-C). Relationship between Ct values of individual and pooled SAL samples.** R and p values determined by Pearson correlation and graphically represented by linear regression. Dotted line indicates the limit of detection. P-value<0.001

## References

- Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S, Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L, Zhong XZ, McGeer AJ, Mubareka S, Toronto Invasive Bacterial Diseases Network C-I. 2020. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis doi:10.1093/cid/ciaa848.
- Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M, Kato K, Imoto Y, Iwata M, Mimura S, Ito T, Tamura K, Kato Y. 2020. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. J Clin Microbiol 58(9):e01438-20. doi: 10.1128/JCM.01438-20.
- 3. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, et al. 2020. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med doi:10.1056/NEJMc2016359.
- 4. Migueres M, Mengelle C, Dimeglio C, Didier A, Alvarez M, Delobel P, Mansuy JM, Izopet J. 2020. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. J Clin Virol 130:104580 doi: 10.1016/j.jcv.2020.104580.
- 5. Skolimowska K, Rayment M, Jones R, Madona P, Moore LSP, Randell P. 2020. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect doi:10.1016/j.cmi.2020.07.015.
- 6. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W, Sungkanuparph S, Phuphuakrat A. 2020. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect doi:10.1016/j.cmi.2020.05.001.
- 7. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 58(8):e00776-20 doi: 10.1128/JCM.00776-20.
- 8. Zhu J, Guo J, Xu Y, Chen X. 2020. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect 81:e48-e50 doi: 10.1016/j.jinf.2020.06.059.
- 9. Landry ML, Criscuolo J, Peaper DR. 2020. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol 130:104567 doi: 10.1016/j.jcv.2020.104567.
- Rao M, Rashid FA, Sabri F, Jamil NN, Zain R, Hashim R, Amran F, Kok HT, Samad MAA, Ahmad N.
  2020. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. Clin Infect Dis doi:10.1093/cid/ciaa1156.
- 11. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM. 2020. Self-Collected Anterior Nasal and Saliva Specimens versus Healthcare Worker-Collected

Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2. J Clin Microbiol doi:10.1128/JCM.01824-20.

- 12. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K, Cavuoti D. 2020. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol 58(8):e01109-20. doi: 10.1128/JCM.01109-20.
- Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, Rubin BP, Terpeluk P.
  2020. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients. J Clin Microbiol doi:10.1128/JCM.01946-20.
- 14. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M, Sessa F, Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020. Saliva is a reliable tool to detect SARS-CoV-2. J Infect 81:e45-e50 doi: 10.1016/j.jinf.2020.04.005.
- 15. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, Sato K, Oguri S, Taki K, Senjo H, Sugita J, Hayasaka K, Konno S, Nishida M, Teshima T. 2020. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect 81:e145-e147 doi: 10.1016/j.jinf.2020.05.071.
- 16. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Shiraki T, Uchida S, Uno S, Kabata H, Ikemura S, Kamata H, Ishii M, Fukunaga K, Kawaoka Y, Hasegawa N, Murata M. 2020. Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol doi:10.1136/jclinpath-2020-206972.
- Byrne RL, Kay GA, Kontogianni K, Aljayyoussi G, Brown L, Collins AM, Cuevas LE, Ferreira DM, Fraser AJ, Garrod G, Hill H, Hughes GL, Menzies S, Mitsi E, Owen SI, Patterson EI, Williams CT, Hyder-Wright A, Adams ER, Cubas-Atienzar AI. 2020. Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis. Emerg Infect Dis 26(11) doi: 10.3201/eid2611.203283.